Abbott Wants New J&J Stent Patent Declared Invalid

Law360, New York (May 16, 2007, 12:00 AM EDT) -- A patent issued Tuesday and assigned to a Johnson & Johnson subsidiary has spawned two lawsuits over the lucrative and highly litigious market for drug-eluting stents.

Johnson & Johnson unit Cordis Corp. filed suit Tuesday in the U.S. District Court for the District of New Jersey, claiming that Abbott Laboratories’ Xience V drug-coated stent infringes U.S. Patent Number 7,217,286. A Cordis spokesman said the patent relates to the use of the drug rapamycin or its analogs on a stent to prevent the buildup of scar tissue...
To view the full article, register now.